---
title: "ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265940155.md"
datetime: "2025-11-14T13:24:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265940155.md)
  - [en](https://longbridge.com/en/news/265940155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265940155.md)
---

# ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 K

Revenue: As of FY2025 Q3, the actual value is USD 1.941 K.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD 334.56 K.

### Segment Revenue

-   **Net Revenue**: For the three and nine months ended September 30, 2025, net revenue was $1,941, with no revenue reported for the same periods in 2024.

### Operational Metrics

-   **Gross Profit**: For the three and nine months ended September 30, 2025, gross profit was $884, with no gross profit reported for the same periods in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended September 30, 2025, were $1,146,381, compared to $215,256 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $17,502,751, compared to $543,149 for the same period in 2024.
-   **Net Loss**: For the three months ended September 30, 2025, net loss was - $1,850,493, compared to - $216,269 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $19,773,114, compared to - $544,162 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $3,995,648, compared to - $744,755 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $5,940,286, compared to $750,122 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Aspire Biopharma Holdings, Inc. plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company intends to submit a section 505(b)(2) NDA for its high-dose aspirin product following positive clinical trial results, with plans to seek FDA 505(b)(2) Fast Track designation in the first quarter of 2026.
-   **Non-Core Business**: Aspire is exploring licensing possibilities for its sublingual melatonin sleep-aid product and has developed formulations for sublingually administered vitamins and semaglutide. The company is also developing caffeine products and considering formulations for other drug classes.

### Related Stocks

- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [SpaceX Earnings Highlights from Cathie Wood's ARK Invest](https://longbridge.com/en/news/295434722.md)
- [Why Is Coherent Stock Falling on Monday?](https://longbridge.com/en/news/295438274.md)
- [Nvidia-Backed Lumentum Soaring Again: Will It Rise or Fall After Earnings?](https://longbridge.com/en/news/295343373.md)
- [Vertrix Wealth Management LLC Has $1.86 Million Stock Holdings in Meta Platforms, Inc. $META](https://longbridge.com/en/news/295387045.md)
- [Wealth Science Advisors LLC Acquires 4,242 Shares of Oracle Corporation $ORCL](https://longbridge.com/en/news/295385665.md)